CXCL12

(redirected from SDF-1)
Also found in: Acronyms, Wikipedia.

CXCL12

A gene on chromosome 10q11.1 that encodes a stromal cell-derived alpha chemokine of the intercrine family which, once bound to its receptor, CXCR4, activates lymphocytes, an interaction that has been implicated in the metastasis of breast and other cancers.

Molecular pathology
CXCL12 mutations are associated with resistance to HIV-1 infections.
References in periodicals archive ?
In contrast to IP-I 0, SDF-1 axis contributes to angiogenesis through induction of proangiogenic factors such as IL-8 and VEGF(10).
About the role of SDF-1 in cancer promotion, it has been reported that myofibroblasts derived-SDF-1 increases the growth of breast cancer cells through _angiogenesis and tumor cells proliferation (15).
They've already begun looking at what happens to SDF-1 in human bone marrow stem cells and have identified a couple of drugs used to treat other conditions that increase SDF-1 production and protection.
It was already known that stem cells secrete SDF-1 and that the cell survival pathway, autophagy, was upregulated in stem cells.
The chemokine SDF-1 is a chemo-attractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.
SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes.
Fish versions of SDF-1 and CXCR4 are critical for the migration of primordial germ cells, other researchers reported in the Nov.
In the mouse, SDF-1 appears to be required for the execution of the last step when the cells colonize the genital ridge which expresses the chemokine," says Erez Raz of the Max Planck Institute for Biophysical Chemistry in Gottingen, Germany, who led the Cell study.
In RegenMed's animal model of proliferative retinopathy (growing vessels into the eye), SDF-1 is expressed in response to injury, and cells are called in to repair the damaged blood vessels.
In the study, researchers attempted to re-establish and extend the time that SDF-1 could stimulate patients' stem cells.
The heart's pumping ability improved, particularly for those receiving the two highest doses of SDF-1 compared to the lowest dose.
We studied SDF-1 gene polymorphisms in polycythemia vera (PV) and essential thrombocythemia (ET) to determine the frequency of the SDF1-3'A polymorphism and to evaluate its impact on susceptibility to these diseases and on the occurrence of thrombotic complications.